Topic Ocrelizumab
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} CRNI® Recertification Units & CE Credit - Infusion Topics: Ocrevus Rapid Infusion Protocol; Pandemic Nurses' Perceptions; Adverse Effects of Hypodermoclysis
Price: $200.00Credits:
- ANCC 6.5 CH
- INCC 10.0 CRNI
- DC - BON 6.5 CH
- FL - BON 6.5 CH
- GA - BON 6.5 CH
- NM - BON 6.5 CH
- SC - BON 6.5 CH
- WV - BOERN 6.5 CH
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: JINNR0323Published: March 2023; Vol 46, No 2Expires: 12/5/2025Sources: Journal of Infusion NursingDetailsRequired Passing Score: 21/30 (70%)Categories: Acute Care , Drug Therapy , Hospital , Infusion Therapy , Preventing Hospital Acquired Conditions (HAC) , Quality Improvement , SafetyTopics: COVID-19 , Hypodermoclysis , Infusion , Intravenous Medication , Ocrelizumab , Pandemic , Patient Safety , Quality Assessment , Transfusion Reactions , Venipuncture -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} CE Credit - Infusion Topics: Ocrevus Rapid Infusion Protocol; Pandemic Nurses' Perceptions; Adverse Effects of Hypodermoclysis
Price: $55.25Credits:
- ANCC 6.5 CH
- DC - BON 6.5 CH
- FL - BON 6.5 CH
- GA - BON 6.5 CH
- NM - BON 6.5 CH
- SC - BON 6.5 CH
- WV - BOERN 6.5 CH
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: JINNC0323Published: March 2023; Vol 46, No 2Expires: 12/5/2025Sources: Journal of Infusion NursingDetailsRequired Passing Score: 21/30 (70%)Categories: Acute Care , Drug Therapy , Hospital , Infusion Therapy , Medical-Surgical , Preventing Hospital Acquired Conditions (HAC) , Quality Improvement , SafetyTopics: COVID-19 , Hypodermoclysis , Infusion , Intravenous Medication , Ocrelizumab , Pandemic , Patient Safety , Quality Assessment , Transfusion Reactions , Venipuncture